Ranolazine attenuates behavioral signs of neuropathic pain.

  title={Ranolazine attenuates behavioral signs of neuropathic pain.},
  author={Harry J. Gould and Colleen J Garrett and Renee R. Donahue and Dennis Paul and Ivan Diamond and Bradley K. Taylor},
  journal={Behavioural pharmacology},
  volume={20 8},
Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
9 Citations
38 References
Similar Papers


Publications citing this paper.
Showing 1-9 of 9 extracted citations


Publications referenced by this paper.
Showing 1-10 of 38 references

SCN 9 A mutations in paroxysmal extreme pain disorder : allelic variants underlie distinct channel defects and phenotypes

  • R Gil-Gouveia, PJ Goadsby
  • Neuron
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…